Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 11.5589 USD -1.04% Market Closed
Market Cap: 612.3m USD
Have any thoughts about
Stoke Therapeutics Inc?
Write Note

Stoke Therapeutics Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Stoke Therapeutics Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Stoke Therapeutics Inc
NASDAQ:STOK
Accounts Payable
$2.5m
CAGR 3-Years
53%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$4B
CAGR 3-Years
215%
CAGR 5-Years
112%
CAGR 10-Years
59%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%
No Stocks Found

Stoke Therapeutics Inc
Glance View

Market Cap
611.9m USD
Industry
Biotechnology

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

STOK Intrinsic Value
4.6759 USD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Stoke Therapeutics Inc's Accounts Payable?
Accounts Payable
2.5m USD

Based on the financial report for Sep 30, 2024, Stoke Therapeutics Inc's Accounts Payable amounts to 2.5m USD.

What is Stoke Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
7%

Over the last year, the Accounts Payable growth was -20%. The average annual Accounts Payable growth rates for Stoke Therapeutics Inc have been 53% over the past three years , 7% over the past five years .

Back to Top